8 Gene Editing Applications Moving from Lab to Clinical Use

8. Hereditary Transthyretin Amyloidosis - Silencing Disease-Causing Genes

Hereditary Transthyretin Amyloidosis (hATTR) represents a unique application of gene editing technology, utilizing in vivo base editing to permanently silence the production of disease-causing transthyretin protein in the liver, offering a potential cure for this progressive and fatal disorder. This rare genetic condition is caused by mutations in the TTR gene that lead to the production of misfolded transthyretin protein, which accumulates as amyloid deposits in various organs, particularly affecting the nervous system and heart. Traditional treatments have focused on stabilizing the abnormal protein or reducing its production through RNA interference, but gene editing offers the possibility of permanently eliminating the source of the problem. The NTLA-2001 treatment by Intellia Therapeutics uses lipid nanoparticles to deliver CRISPR-Cas9 components directly to liver cells, where they create precise cuts in the TTR gene to permanently reduce transthyretin production. Clinical trial results have demonstrated sustained reductions in disease-causing protein levels of up to 87% after a single treatment, with effects lasting for months and showing potential for permanent correction. This approach is particularly significant because it represents one of the first successful applications of in vivo gene editing for a systemic genetic disorder, proving that gene editing can be safely and effectively delivered to internal organs. The treatment's success has implications beyond hATTR, potentially paving the way for similar approaches to other liver-produced disease proteins and establishing important precedents for in vivo gene editing safety and efficacy. The ability to achieve such dramatic and sustained effects with a single treatment represents a paradigm shift from chronic disease management to potential cures, offering hope for patients with this devastating condition and their families.